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Platelets play an important role in the pathogenesis and the ischemic complications of
atherosclerosis. Platelets may be activated by several different agonists, promoting the
release of their granule contents and subsequent aggregation and thrombus formation; this
leads to ischemic events such as myocardial infarction or stroke. Aspirin, the most popular
antiplatelet agent, is a cornerstone in the treatment and prevention of ischemic events in
cardiovascular patients. It inhibits a particular ampliﬁcation pathway of platelet activation,ne A2 (TxA2) generation. However, despite a consistent inhibition ofeywords: based on thromboxalatelet reactivity
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TxA2 production, a substantial proportion of patients display preserved platelet function.
This phenotype is deﬁned as “high on-treatment platelet reactivity”. It is a risk factor for
the  recurrence of ischemic events, particularly in acute vessel injury settings. The determi-
nants of platelet reactivity in these patients remain unclear, but previous studies, including
healthy subjects, suggested that it is genetically determined.
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Over the last decade, technological improvements have led to the development of highly efﬁ-
cient omics strategies. High-throughput genomics, transcriptomics and proteomics have the
potential to dissect ﬁne metabolic modulations. However, the bioinformatics management
of  these large data sets remains a challenging issue. Network biology approaches permit
the  integration of different omics data sets and the identiﬁcation of mutual interactions
between gene products and/or molecules. The inherent topology of the network can be
then explored at a pathway level rather than at a gene level. Network biology constitutes
an  efﬁcient tool to further explore platelet metabolism and defects, such as modulators of
platelet reactivity in cardiovascular patients.
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1.  Introduction
Platelets are small anucleated cell fragments also called
thrombocytes [1]. With a diameter of 2–4 m,  they are the
smallest cellular components of the bloodstream. Although
platelets do not contain a nucleus, they can alter their pro-
tein proﬁle by splicing and translation of a limited batch
of messenger ribonucleic acids (mRNA) inherited from their
parent cell, the megakaryocyte [2–4]. Megakaryocytes are
highly specialized hematopoietic cells [5], which derive from
hematopoietic stem cells. They become polyploid (4–64 N)
through several cycles of endomitosis [6–8]. In addition, a
cytoplasmic maturation occurs involving the formation of
a demarcation membrane system (DMS) and the accumu-
lation of cytoplasmic proteins and secretory granules [6,9].
The DMS  is supposed to function as a membrane reserve
for pro-platelet formation and constitutes the open canalic-
ular system in mature platelets [5]. Granule number increases
with megakaryocyte maturation. With an average lifespan of
10 days before being phagocytosed by the spleen or the liver
[10], approximately 1011 platelets must be produced every day
(around 10% renewal) [8] to ensure an average concentration
of 150–400 × 109 platelets/L [11].
Platelet production is mainly regulated by thrombopoietin.
process since pro-platelets contain active caspase-3 and 9 and
their production is decreased by anti-caspase agents [11,12].
Mature platelets have a large number of secretory gran-
ules. They also contain endoplasmic reticulum and Golgi, as
well as translation machinery. In addition, a few mitochon-
dria are also visible under electronic microscopy, together with
glycogen particles and a large cytoskeleton [5].
1.1.  Platelets  and  atherothrombosis
Platelets are usually activated following vessel injury, but they
are also involved in the progression of atherosclerotic plaques
in high shear stress conditions (Fig. 1) [13]. Cardiovascular (CV)
diseases, including arterial thrombosis, are the most common
cause of mortality in developed countries [14] and platelets are
key-targets for the treatment and the prevention of ischemic
events. Upon inﬂammation [15], endothelial cells are acti-
vated and recruit platelets to the site of atherosclerotic plaque
formation [10,13], together with adhesive molecules which
stimulate migration of smooth muscle cells and monocytes
[16]. In mice, deletion of the TxA2 receptor delays plaque
development, illustrating the role of platelets in atheroscle-
rotic plaque formation [13,17]. Moreover, activated platelets
also release adhesive molecules in the nascent plaque, thus
 © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.This humoral factor is produced in the liver and the kid-
neys, and stimulates the production of thrombocytes in bone
marrow, from their hematopoietic cell of origin, the megakyry-
ocyte [5,8]. Cell apoptosis is also involved in the regulationenhancing the effect of endothelium activation on plaque pro-
gression. For instance, p-selectin and chemokines released
from platelets activate monocytes that migrate into the
plaque and increase the local inﬂammation process (Fig. 1).
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Fig. 1 – Atherosclerotic plaque formation.
Platelets are involved in the atherosclerotic process; they
secrete factors, which induce monocyte recruitment,
enhance inﬂammation and cell proliferation, and promote
thrombus formation. All together, these processes favor
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Fig. 2 – Antiplatelet drugs.
The main ampliﬁcation pathways are targeted by aspirin
(thromboxane, in red) and anti-P2Y12, such as clopidogrel
(adenosine diphosphate (ADP), in green). IIbIIa: IIb3, PDE:
Phosphodiesterase, TxA2: Thromboxane A2. (For
interpretation of the references to color in this ﬁgure legend,laque expansion.
ctivation of endothelial cells and the expression of tis-
ue factor increase the thrombogenic potential of plaques
13]. In addition, platelets release TxA2, which increases
nﬂammation by its vasoconstricting action [5] and promotes
latelet aggregation and local platelet recruitment (Fig. 1)
15]. The lesion is then covered by a ﬁbrous cap. Rupture
f an atherosclerotic plaque occurs by ulceration or erosion,
nder the effect of inﬂammation and/or enzymes released by
mmune cells. Platelets are key components in the subsequent
hrombus formation, which can occlude the artery and results
n organ infarction [16].
.2.  Antiplatelet  drugs
ince platelets play a major role in atherosclerosis and throm-
us formation, antiplatelet agents belong to the ﬁrst line
f treatment in CV diseases [18]. The main oral antiplatelet
rugs target two important ampliﬁcation pathways of platelet
ctivation: TxA2 production and the action of adenosine
iphosphate (ADP, Fig. 2).
Aspirin (acetylsalicylic acid) is the oldest anti-platelet drug
sed in CV diseases [19]. It irreversibly acetylates platelet
yclooxygenase-1 (Cox-1) serine 529 and inhibits TxA2 pro-
uction, thus impairing platelet activation [5] (Fig. 3). A low
ose of aspirin (75–325 mg/day) is usually prescribed because
t induces an almost complete inhibition of platelet Cox-
. However, in nucleated cells, such as endothelial cells,
yclooxygenase causes a minimal level of acetylation duethe reader is referred to the web version of the article.)
to its higher turnover. In addition, Cox-2, which is predomi-
nantly expressed in endothelial cells, presents a limited level
of acetylation with low doses of aspirin. Thus, endothelial cell-
derived eicosanoïd production is barely affected by low doses
of aspirin. Moreover, using lower doses of aspirin minimizes
the inhibition of prostaglandins and its related gastrointesti-
nal tract side effects [18]. Several clinical studies showed that
aspirin is associated with a 25% relative decrease in the risk of
vascular death, stroke and myocardial infarction in high risk
patients [20].
Clopidogrel belongs to the anti-P2Y12 thienopyridine fam-
ily, which are pro-drugs metabolized into an active compound
by several P-450 cytochromes (CYP450) in the liver. It acts on
the ADP receptor P2Y12 (Fig. 2), by covalent modiﬁcations of
two cysteine residues. The P2Y12 receptor is important for
the ampliﬁcation of the platelet activation process, not only
when platelets are stimulated with ADP, but also with other
agonists such as collagen [5]; it also plays a major role in
thrombus formation in high shear stress conditions [21]. At the
maintenance dose of 75 mg/day, maximal pharmacodynamic
effect is reached between days 5 and 7 [22]. This delay between
drug intake and antiplatelet effect can be partially overcome
by the administration of an initial loading dose (600 mg).
Patients at high risk of ischemic event (for instance after
an acute coronary syndrome and/or percutaneous coronary
intervention) are usually treated by using a dual anti-platelet
therapy with aspirin and an anti-P2Y12 drug for between
1 and 12 months. Although it combines the advantages of
both drugs, the efﬁcacy of this treatment may be limited by
compensatory platelet activation pathways partially restor-
ing platelet reactivity [18]. Contrary to acute settings, the dual
 t e o m28  t r a n s l a t i o n a l p r o
antiplatelet therapy is generally not recommended in stable
cardiovascular patients [22].
The delay and the variability of the pharmacodynamic
effect of clopidogrel promoted the development of more
efﬁcient anti-P2Y12 drugs, such as prasugrel, a third genera-
tion thienopyridine drug, and ticagrelor, a non-thienopyridine
molecule.
Other platelet receptors or pathways are targeted by
antiplatelet drugs. Integrin IIb3, for instance, is antag-
onized by several compounds (eptiﬁbatide, abciximab or
tiroﬁban), which are administered intravenously (Fig. 2). These
treatments are often prescribed to patients in acute clini-
cal situations [18,22]. Phosphodiesterase inhibitors, such as
cilostazol and dipyridamole, increase levels of cyclic adeno-
sine monophosphate, inhibiting platelet activation (Fig. 2) [22].
These latter drugs have speciﬁc side effects that limit their use
in daily practice. Other antiplatelet drugs with new targets,
Fig. 3 – TxA2 production pathway.
Phospholipids in the plasma membrane and arachidonic
acid are substrates of the TxA2 synthesis pathway. Cox-1
metabolizes arachidonic acid into prostaglandin G2, which
is the substrate of hydroxyperoxidase. The product is
prostaglandin H2, which is transformed into TxA2 by TxA2
synthase. Finally, an autocrin and paracrin interaction of
TxA2 with its receptor (TP receptor) triggers a G-protein
activation cascade. Aspirin inhibits this pathway by
acetylation of Cox-1. i c s 1 ( 2 0 1 3 ) 25–37
such as the thrombin receptor PAR-1 or the collagen receptor
GPVI, are in development [23,24].
1.3.  Determinants  of  platelet  reactivity  and  risk  of
recurrence  of  ischemic  events
Biological evaluation of platelet reactivity in CV patients
treated with antiplatelet drugs shows that the efﬁcacy of the
drugs can vary between patients and that a signiﬁcant propor-
tion of treated patients are deemed “non-responders”, “poor
responders” or “resistant”. This is because their platelet reac-
tivity is higher and can even reach a level similar to that of
patients without antiplatelet drug treatment [25]. Although
lack of compliance is the most common cause of non response,
variability of on-treatment platelet reactivity still exists in
documented compliant patients. The term “resistance” to a
drug should be used when a drug is unable to hit its phar-
macological target [25] i.e. when aspirin is unable to inhibit
platelet-derived Cox-1-dependent TxA2 production, or when
clopidogrel is unable to inhibit the P2Y12 platelet receptor.
As a consequence, with regard to aspirin response, resistance
refers to assays evaluating TxA2’s stable breakdown product
(serum TxB2). With regard to clopidogrel response, resistance
refers to the speciﬁc evaluation of P2Y12 receptor inhibition
(using quantiﬁcation of the phosphorylation status of the
vasodilator phosphoprotein [VASP assay]) [25]. The term “high
on-treatment platelet reactivity” relates more  to platelet func-
tion assessed with non-speciﬁc assays (aggregation-based
assays) that provide a more  global evaluation of platelet reac-
tivity.
Several genetic and non-genetic factors have been associ-
ated with the variability of antiplatelet drug response [26], but
these factors explain only a small proportion of the observed
variability. There is however a major difference between the
causes of the variability of aspirin response in comparison
to clopidogrel response. The biological response to the latter
antiplatelet drug is mainly mediated by the efﬁciency of the
metabolization of the pro-drug and thus by the concentration
of the active metabolite that is driven by esterases and liver
CYP [27]. Clopidogrel response is thus mostly determined by
liver-related factors. Conversely, speciﬁc assays revealed that
aspirin has a much more  homogeneous effect, with more  than
95% of TxA2 production being inhibited in the vast major-
ity of patients [25]. However, when using aggregation-based
assays, a signiﬁcant proportion of CV patients (around 30%)
displayed preserved platelet function despite adequate inhi-
bition of platelet-derived TxA2 production [28]. This ﬁnding
points to platelet-related factors that may overcome aspirin’s
inhibition of the TxA2 pathway. Aspirin may thus reveal
compensatory mechanisms that allow platelet aggregation to
occur despite TxA2 inhibition, and cardiovascular patients
treated with aspirin as their sole antiplatelet drug are of par-
ticular interest for the identiﬁcation of these compensatory
pathways [29].
The platelet activation pathways that might modulate
platelet reactivity in aspirin-treated CV patients are not
known. Pioneering studies addressed the issue of the hetero-
geneity of platelet reactivity in healthy subjects. They showed
that a phenotype of “platelet hyperreactivity” is found in
around 14% of this population [30]. Moreover, it has been
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hown that this phenotype is strongly heritable, global (not
gonist-speciﬁc), stable over time and barely affected by CV
isk factors [30–33]. Moreover, platelet hyperreactivity was
hown to be independent of aspirin intake [34], i.e. subjects
ith platelet hyperreactivity without aspirin treatment still
isplayed platelet hyperreactivity on treatment. The strong
ereditary feature of platelet reactivity [32] points to a genetic
ontrol.
Increased platelet reactivity in aspirin-treated patients was
epeatedly associated with recurrence of ischemic events, at
east in acute event settings such as acute coronary syn-
romes, stroke or percutaneous coronary intervention [35–37].
owever, it does not seem to affect cardiovascular outcome in
table patients [38]. Overall, there is a 2- to 4-fold increased risk
f a recurrent ischemic event in patients with a high on-aspirin
r on-clopidogrel platelet reactivity. Interestingly, it has been
uggested that, in order to identify cardiovascular patients at
isk of ischemic events, platelet reactivity should be evalu-
ted with a panel of methods exploring different aggregation
athways [39]. Altogether, these data suggest that platelet
eactivity modulates the risk of recurrence of ischemic events
n cardiovascular patients in acute vessel injury settings, inde-
endently of the method of platelet function evaluation. This
trengthens the hypothesis that a common factor modulates
latelet reactivity.
.  Omics  strategies  relevant  to  platelet
eactivity
ecent improvements in high-throughput genetic, transcrip-
omic and proteomic techniques, as well as in bioinformatics
ethods, have advanced our knowledge of platelet reactivity
hysiology. These tools have allowed the analysis of hundreds
f gene characteristics and products at the same time and
an give a picture of all the actors of a given functional
athway [40–42]. Automated lab-on-a-chip methods in tran-
criptomics and genetics make possible large scale studies of
uman samples [43]. Moreover, highly sensitive mass spec-
rometers, such as Orbitrap [44], coupled with an efﬁcient
eparation method such as off-gel electrophoresis [45], can
etect small amounts of proteins in complex samples. These
trategies are complementary and versatile. Moreover, there is
 small overlap between platelet proteome and transcriptome
nformation [2,40], which highlights the beneﬁt of combining
everal strategies to learn more  about platelet physiology.
.1.  Genetics  of  single  nucleotide  polymorphism
latelet reactivity has been shown to vary between individ-
als, but is strongly inherited, implying a genetic contribution
o platelet function [32,46,47]. Several genetic studies were
ade based on a candidate gene approach, targeting genes
nown to be involved in platelet function (Table 1) [48,49].
The association studies regarding putative genetic vari-
nts and platelet reactivity face several challenges. These
nclude the number of subjects, the ethnic homogeneity of
he population and the biological assay to assess platelet reac-
ivity. The ﬁrst attempts to identify the genetic causes of
he modulators of platelet reactivity used a candidate gene c s 1 ( 2 0 1 3 ) 25–37 29
approach–targeting genes known to be involved in platelet
activation processes (Table 1). Over the last decades, to better
discriminate the DNA loci implicated in phenotypic variabil-
ity, genome-wide association studies (GWAS) were performed.
These studies aimed to identify associations between millions
of genetic variants and platelet reactivity. Their major draw-
back was the management of false positive results due to the
large number of associations tested.
This approach has been applied to investigate the genetic
basis determining platelet morphology, such as mean platelet
volume or platelet count [48,49]. The ﬁrst GWAS meta-analysis
of platelet function was published in 2010 [50]. Two Euro-
pean ancestry cohorts of 4000 subjects in total were tested
for aggregation to epinephrine, ADP and collagen. Seven loci
were found to be associated with platelet aggregation results
in both cohorts, with variable effect depending on the ago-
nists (Table 1). These loci were also tested in an independent
cohort of African ancestry and all but one of the seven loci was
replicated in it.
Several common genes were found (PEAR1, GP6 and
ADRA2A for example) using GWAs and a candidate gene
approach, although the SNPs may be different within the same
locus. Platelet endothelial aggregation receptor-1 (PEAR1) is
phosphorylated upon platelet activation and plays a role in
the ampliﬁcation process of IIb3 activation [51]. It has been
shown to be related to epinephrine response, but also to ADP
and collagen responses [50]. Glycoprotein VI (GP6) is a collagen
receptor and, as expected, is associated with collagen-induced
platelet activation. The reported SNP (producing a H322N,
rs1671152) may decrease the interaction of GPVI with its
downstream effectors, Fyn and Lyn pathways, and thus the
subsequent collagen response [49]. The adrenoceptor  2A
(ADRA2A) is the major epinephrine receptor in platelets [49].
This latter gene is of particular importance since epinephrine-
induced platelet aggregation is considered the most reliable
marker of platelet reactivity [33]. Despite some plausibility
related to the function of this gene, genetics alone can only
explain a minority of the variance of parameters in cardiovas-
cular diseases, such as mean platelet volume [52] or platelet
reactivity [53].
2.2.  Transcriptomics
Platelets are anucleated cell fragments, but they do contain
rough endoplasmic reticulum and ribosomes. Several stud-
ies showed that protein synthesis occurs in platelets [3,54].
Moreover, platelets contain a stable pool of mRNAs, which
is involved in platelet function and life-span, hemostasis
and inﬂammation [55]. In addition, this pool decreases with
platelet age and is thus an indicator of platelet turnover [55].
Platelets are estimated to contain around 5000 different mRNA
transcripts [55] covering approximately half of the megakary-
ocyte transcriptome. The content of mRNA  also varies with
platelet activation or certain diseases, such as systematic
lupus erythematosus [55,56]. Platelet mRNAs  are translated
in different modes depending on the ﬁnal protein and its role
(Fig. 4). A small number of mRNAs are highly abundant and
constitutively translated into proteins. These include actin,
IIb3 and von Willebrand factor (vWF) (Fig. 4(1)). On the other
hand, B-cell lymphoma protein-3 (Bcl-3), which is involved
30  t r a n s l a t i o n a l p r o t e o m i c s 1 ( 2 0 1 3 ) 25–37
Table 1 – Candidate genes associated with platelet function. Several genes were  associated with modulation of platelet
reactivity using GWAS approach or by functional genomics. FG: functional genomics, GWAS: genome-wide association
study, TGS: targeted-gene study.
Entry name Protein names Gene names Method of
identiﬁcation
ADA2A HUMAN Alpha-2A adrenergic receptor (Alpha-2 adrenergic receptor subtype
C10) (Alpha-2A adrenoreceptor) (Alpha-2A adrenoceptor)
(Alpha-2AAR)
ADRA2A ADRA2R
ADRAR
GWAS, TGS
AKT2 HUMAN RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase
Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta)
AKT2 FG
CD36 HUMAN Platelet glycoprotein 4 (Fatty acid translocase) (FAT) (Glycoprotein IIIb)
(GPIIIB) (Leukocyte differentiation antigen CD36) (PAS IV) (PAS-4)
(Platelet collagen receptor) (Platelet glycoprotein IV) (GPIV)
(Thrombospondin receptor) (CD antigen CD36)
CD36  GP3B GP4 FG
FCERG HUMAN High afﬁnity immunoglobulin epsilon receptor subunit gamma (Fc
receptor gamma-chain) (FcRgamma) (Fc-epsilon RI-gamma) (IgE Fc
receptor subunit gamma) (FceRI gamma)
FCER1G FG
FCG2A HUMAN Low afﬁnity immunoglobulin gamma Fc region receptor II-a (IgG Fc
receptor II-a) (CDw32) (Fc-gamma RII-a) (Fc-gamma-RIIa) (FcRII-a) (CD
antigen CD32)
FCGR2A  CD32 FCG2
FCGR2A1 IGFR2
TGS
GBB3 HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
(Transducin beta chain 3)
GNB3  TGS
GNAZ HUMAN Guanine nucleotide-binding protein G(z) subunit alpha (G(x) alpha
chain) (Gz-alpha)
GNAZ  FG
GP1BA HUMAN Platelet glycoprotein Ib alpha chain (GP-Ib alpha) (GPIb-alpha) (GPIbA)
(Glycoprotein Ibalpha) (Antigen CD42b-alpha) (CD antigen CD42b)
[Cleaved into: Glycocalicin]
GP1BA  TGS
GPVI HUMAN Platelet glycoprotein VI (GPVI) (Glycoprotein 6) GP6 GWAS, FG, TGS
ITA2 HUMAN Integrin alpha-2 (CD49 antigen-like family member B) (Collagen
receptor) (Platelet membrane glycoprotein Ia) (GPIa) (VLA-2 subunit
alpha) (CD antigen CD49b)
ITGA2  CD49B FG, TGS
ITA2B HUMAN Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane
glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb
heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb
light chain, form 2]
ITGA2B  GP2B ITGAB TGS
ITB3 HUMAN Integrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD
antigen CD61)
ITGB3  GP3A TGS
ITPR1 HUMAN Inositol 1,4,5-trisphosphate receptor type 1 (IP3 receptor isoform 1)
(IP3R 1) (InsP3R1) (Type 1 inositol 1,4,5-trisphosphate receptor) (Type 1
InsP3 receptor)
ITPR1  INSP3R1 FG
JAK2 HUMAN Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2) JAK2 FG
JHD2C HUMAN Probable JmjC domain-containing histone demethylation protein 2 C
(EC 1.14.11.-) (Jumonji domain-containing protein 1 C) (Thyroid
receptor-interacting protein 8) (TR-interacting protein 8) (TRIP-8)
JMJD1C JHDM2C
KIAA1380 TRIP8
GWAS
MK14 HUMAN Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC
2.7.11.24) (Cytokine suppressive anti-inﬂammatory drug-binding
protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2)
(MAX-interacting protein 2) (Mitogen-activated protein kinase p38
alpha) (MAP kinase p38 alpha) (Stress-activated protein kinase 2a)
(SAPK2a)
MAPK14 CSBP CSBP1
CSBP2 CSPB1 MXI2
SAPK2A
FG
MP2K2 HUMAN Dual speciﬁcity mitogen-activated protein kinase kinase 2 (MAP
kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2)
(MAPK/ERK kinase 2) (MEK 2)
MAP2K2  MEK2 MKK2
PRKMK2
FG
MP2K4 HUMAN Dual speciﬁcity mitogen-activated protein kinase kinase 4 (MAP
kinase kinase 4) (MAPKK 4) (EC 2.7.12.2) (JNK-activating kinase 1)
(MAPK/ERK kinase 4) (MEK 4) (SAPK/ERK kinase 1) (SEK1)
(Stress-activated protein kinase kinase 1) (SAPK kinase 1) (SAPKK-1)
(SAPKK1) (c-Jun N-terminal kinase kinase 1) (JNKK)
MAP2K4 JNKK1
MEK4 MKK4 PRKMK4
SEK1 SERK1 SKK1
MRVI1 HUMAN Protein MRVI1 (Inositol 1,4,5-trisphosphate receptor-associated cGMP
kinase substrate) (JAW1-related protein MRVI1)
MRVI1  IRAG JAW1L GWAS
P2RY1 HUMAN P2Y purinoceptor 1 (P2Y1) (ATP receptor) (Purinergic receptor) P2RY1 TGS
P2Y12 HUMAN P2Y purinoceptor 12 (P2Y12) (ADP-glucose receptor) (ADPG-R)
(P2T(AC)) (P2Y(AC)) (P2Y(cyc)) (P2Y12 platelet ADP receptor) (P2Y(ADP))
(SP1999)
P2RY12 HORK3 FG, TGS
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Table 1 (Continued)
Entry name Protein names Gene names Method of
identiﬁcation
PAR1 HUMAN Proteinase-activated receptor 1 (PAR-1) (Coagulation factor II receptor)
(Thrombin receptor)
F2R  CF2R PAR1 TR TGS
PEAR1 HUMAN Platelet endothelial aggregation receptor 1 (hPEAR1) (Multiple
epidermal growth factor-like domains protein 12) (Multiple EGF-like
domains protein 12)
PEAR1  MEGF12 GWAS, FG
PGH1 HUMAN Prostaglandin G/H synthase 1 (EC 1.14.99.1) (Cyclooxygenase-1)
(COX-1) (Prostaglandin H2 synthase 1) (PGH synthase 1) (PGHS-1) (PHS
1) (Prostaglandin-endoperoxide synthase 1)
PTGS1  COX1 TGS
PK3CG HUMAN Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit
gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma)
(PI3Kgamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.153)
(Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic
subunit gamma) (PtdIns-3-kinase subunit p110-gamma) (p110gamma)
(Phosphoinositide-3-kinase catalytic gamma polypeptide)
(Serine/threonine protein kinase PIK3CG) (EC 2.7.11.1) (p120-PI3 K)
PIK3CG GWAS
RAF1 HUMAN RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1)
(Proto-oncogene c-RAF) (cRaf) (Raf-1)
RAF1  RAF FG
SHH HUMAN Sonic hedgehog protein (SHH) (HHG-1) [Cleaved into: Sonic hedgehog
prod
SHH  GWAS
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TA2R HUMAN Thromboxane A2 receptor (TXA2-R) (Prostano
VAV3 HUMAN Guanine nucleotide exchange factor VAV3 (VA
n clot retraction, is translated upon thrombin activation and
nder mammalian target of rapamycin (mTOR) regulation, as
hown in Fig. 4(2). Thrombin activation also increases synthe-
is of continuously translated proteins, such as plasminogen
ctivator inhibitor (PAI-1). Finally, protein synthesis can also
ccur via a functional spliceosome, which has been found
n platelets [4]. Indeed, pre-mRNAs exist in platelets and are
pliced upon platelet activation (Fig. 4(3)). Tissue factors and
nterleukin 1  are examples of such regulation.These different regulation mechanisms are facilitated by a
trong interaction of mRNAs and protein synthesis machin-
ry with the cytoskeleton, and the presence of translation
ig. 4 – The different mRNA  regulation pathways in
latelets.
1) Pool of abundant mRNAs, which are constitutively
ranslated in resting platelets or which are degraded during
latelet maturation. (2) Inducible pool of mature mRNAs
pon platelet activation and under mTOR  regulation. (3)
ool of pre-mRNAS, which are spliced and translated
epending on platelet activation (secondary regulation).
rom Harrison P, Goodall AH. “Message in the
latelet”–more than just vestigial mRNA! Platelets.
008;19:395–404. With permission.uct]
 receptor) TBXA2R TGS
VAV3 FG
factors such as protein eukaryotic initiation factor, which is
constitutively expressed. Platelet activation triggers a drastic
cytoskeleton remodeling, which changes the localization of
the different partners of protein synthesis.
Platelet transcriptome was investigated in the context
of the variability of platelet reactivity. RNA expression was
assessed in 288 healthy individuals using microarray [57]. The
expression level of VAMP8/endobrevin was positively asso-
ciated with high platelet reactivity, as assessed with light
transmission aggregometry. In addition, a SNP (rs1010) and
a microRNA (miRNA-96) were shown to be key players in
VAMP8 modulation. Since VAMP8 is a v-SNARE involved in
the targeting and fusion of secretory granules to the plasma
membrane, this study linked platelet reactivity variability to
granule release.
Recent data suggest that microRNA (miRNA) play an
important role in mRNA  regulation in platelets. These small
nucleotides (around 22 base pairs) can induce mRNA  degra-
dation and either delay or promote translation [58]. Several
mRNAs and their modulating miRNAs were recently associ-
ated with platelet reactivity in healthy subjects [59]. Among
the 284 miRNAs expressed by platelets, 74 were differentially
expressed in different platelet reactivity categories. These
data were combined with quantitative transcriptomic results
on the same cohort, to obtain a list of paired miRNAs-mRNAs
with a binding site at the 3′untranslated region (UTR) of mRNA.
Among them, 3 pairs were of particular interest and could be
validated at the level of protein expression.
Although mRNAs and miRNAs play a role in the modula-
tion of platelet function by transcriptomics, their exact role at
the proteomic level, as well as their functional impact, remain
unclear.2.3.  Proteomics
Platelets have been extensively analyzed using proteomics
[42,60]. Indeed, since platelets are anucleated and contain a
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limited amount of mRNA,  their proteome is interesting for the
study of their physiology. Recently, the platelet proteome was
dramatically extended to reach almost 4000 proteins and 2500
phosphorylation sites [40]. In order to cover as much of the
platelet proteome as possible, the authors combined several
strategies: this involved 2 complementary phosphopeptide
enrichments and the inclusion of a data set of membrane pro-
teins from a previous study [61]. They also estimated the copy
number of 3718 proteins in their sample, using a normalized
spectral abundance factor; this reﬂects the spectral count of a
protein versus its length as a measure of its abundance. This
estimation ranged from 2.2 × 106 to less than 500 proteins. In
addition, they also assessed the proteome variation by rela-
tive quantitative mass spectrometry in platelets isolated from
4 different donors. They concluded that 85% of the 1900 pro-
teins quantiﬁed showed almost no biological variation. This
type of work represents a baseline for any project dedicated
to the study of platelet function. Of note, data mining is an
essential step after proteomic analysis and the integration
of the protein–protein interactions to construct the identiﬁed
pathways is called systems strategy and allows identifying
clusters, i.e. groups of proteins, for further functional vali-
dation [62]. Proteomics has been used to study several diseases
triggered by genetic variants and affecting platelet reactiv-
ity, such as gray platelet syndrome [63] or cystic ﬁbrosis [64].
Other pathologies associated with platelet function modula-
tion were also explored, such as arterial thrombosis [65] or
acute coronary syndrome [66]. Proteomics was also used to
investigate the impact of aspirin or clopidogrel on platelet
function [67] [68]. However, there is limited proteomics data
regarding the investigation of platelet reactivity variability.
The proteins involved in the cytoskeleton (gelsolin precur-
sor isotype 2 and 3, and F-actin capping protein isotype 1) were
found by 2-dimensional gel electrophoresis down-regulated
in stable cardiovascular patients under aspirin treatment
and presenting a high platelet reactivity. This had been
assessed using a Platelet Function Analyzer 100 (PFA-100TM,
Siemens, Marburg, Germany) [69]. These patients also showed
a modulation of proteins involved in glycolysis (GAPDH and
1,6-bisphosphate aldolase) and in oxidative stress (heat shock
protein 71 and 60, and glutathione S-transferase), which could
lead to an increased turnover of platelets and might explain a
poor response to aspirin treatment.
2.4.  Omics  text  mining
As described above, several studies tried to identify genes
potentially responsible for the variability of platelet reactivity
in CV patients or in healthy subjects. They used several meth-
ods to select patients and several analytical approaches based
on SNPs [32,48,49,70,71], proteins [69], or a combination of the
two [57]. However, they all focused on gene products taken sep-
arately. In addition, apart from a few exceptions such as PEAR1
or GP6, patient samples from these different studies may show
inconsistency at the gene product level, but more  homogene-
ity at the level of the pathways they belong to. We mapped
these published results onto a metabolic diagram in order to
assess whether modulated pathways were similar (Fig. 5).
Many genes coding for platelet agonist receptors were
found: TxA2 receptor (TP), epinephrine receptor (ADRA2A), i c s 1 ( 2 0 1 3 ) 25–37
ADP receptors (P2Y1, P2Y12), thrombin receptors (PAR-1), col-
lagen receptors (GP6 and its co-factor FCER1G, ITA2), vWF
receptor complex (GPIb-IX-V and FCG2A), heparin receptor
(HSBP1), HSBP1 receptor (CD36), integrin IIb3 (ITGA2B and
ITGB3) and 2 genes which may play a role in its activation
(PEAR-1 [51] and PDIA3 [72]). Moreover, genes involved in the
signaling pathways downstream of these receptors were also
found to be affected, such as G proteins (GNAZ and GNB3)
and mitogen-activated protein kinase (MAPK) related genes
(AKT2, RAF1, MAPK14, MAP2K2, MAP2K4, VAV3, PIK3GC and
JAK2). On the other hand, 2 genes responsible for intracel-
lular calcium release were also found to be associated with
platelet reactivity (ITPR1 and MRVI1). In addition, a chloride
channel (CLIC1) may also be involved in calcium homeostasis
[69]. Going downstream in the process, platelet reactivity may
also depend on cytoskeleton and cytoskeleton-related genes
(CAPZ, GSN, IPCEF1 and GDR1), as well as glycolysis enzymes
(ALDOA, GAPDH and LDHAL6A). It is of note that some of these
glycolytic enzymes are known to physically interact with actin
for modulation, such as GAPDH and ALDOA [73]. VAMP8, which
is involved in secretory granule release, as well as MME,  a
secreted metalloprotease, were also identiﬁed as associated
with platelet reactivity [57]. Protein synthesis is also an impor-
tant phase of platelet activation and some genes, which may
be involved at different levels of regulation were published
(JHP2C, ANKS1B, GLIS3, HSPA8, JMJD1C AND SHH). Finally, 2
genes related to oxidative stress were associated with platelet
reactivity variability (GSTP1 and HSPD1) (Fig. 5 and Table 2).
In summary, literature mining showed candidates of inter-
est along several crucial pathways for platelet activation and
aggregation, i.e. platelet activation, integrin IIb3 aggre-
gation, signal transduction, calcium metabolism, glycolysis,
cytoskeleton dynamics, oxidative stress, protein synthesis
and secretory granule release. These pathways constitute
possible modulators of platelet reactivity, however the exact
role of each pathway and their effects on each other remain
unclear and require further exploration.
3.  Network  biology:  a  new  paradigm  to
dissect  platelet  reactivity
The molecular biology paradigm assuming a direct, one-way
relationship between proteins has recently been challenged by
the emergence of the network biology paradigm, which takes
into account the contextual links between gene products, but
also other molecules (Fig. 6) [74]. Indeed, a linear pathway
implies that downstream function is unilaterally affected by
upstream modulation, but not the opposite. Network biology
goes beyond this linear pathway representation; it allows the
representation of mutual inﬂuences between interactions.
This can be depicted as nodes representing molecules of
interest (gene products, but also co-factors, small molecules
or drugs), which are linked by lines representing any kind
of direct and indirect relationship (physical interaction,
functional connection or expression-level correlation). These
networks are thus at the interface between genotype and
phenotype [74]; they therefore require a more  global view
of biological processes (achieved by large scale, quantitative
omics methods) and the development of new approaches
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Fig. 5 – Diagram of the metabolic pathways associated with platelet reactivity including the 2 selected clusters.
The genes involved in the generic pathways (G protein, MAP  kinase signaling pathway, oxidative stress, actin binding
proteins and cytoskeleton dynamics, protein synthesis and glycolysis) are listed in Table 2 (IIbIIa: IIb3, composed of
I
a
I
(
p
b
s
p
cTGA2B and ITGB3).
nd new tools to integrate data sets of different origins.
n the platelet ﬁeld, a web-based tool, called PlateletWeb
http://plateletweb.bioapps.biozentrum.uni-wuerzburg.de/
lateletweb.php), has been developed as a database work-
ench centered on literature reviewing to study platelet
ignaling [75].At the heart of network biology is the concept that a
articular clinical phenotype or disease trait is rarely the
onsequence of a single gene, but rather reﬂects the altered
Table 2 – List of the genes associated with platelet reactivity be
synthesis, cytoskeleton and glycolysis.
Pathways 
Signal transduction G protein 
MAPkinase 
Oxidative stress 
Protein synthesis 
Cytoskeleton Actin-binding 
Glycolysis interactions of many  interconnected genes [76]. The observa-
tion of such interactions and their representation in the form
of graphs or networks, can allow scientists to gain a more
systems-level view of an experiment or series of experiments.
Many  different types of molecular networks exist in biology.
For example, protein interaction networks represent physi-
cal interactions between proteins [77,78]; metabolite networks
link metabolites participating in the same biochemical reac-
tions [79,80]; regulatory networks represent transcription
longing to signal transduction, oxidative stress, proteins
Genes
GNAZ, GNB3
AKT2, RAF1, MAPK14, JAK2, MAP2K2, MAP2K4, VAV3, PIK3GC
GSTP1, HSPD1
JHP2C, ANKSI1B, GLIS3, HSPA8, JMJD1C, SHH
CAPZ, GSN, IPCEF1, GDIR1
ALDOA, GAPDH, LDHAL6A
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Fig. 6 – Pathway visualization.
Network representation includes nodes, which represent
the molecules of interest, linked by lines which stand for
relationships between nodes. A cluster corresponds to a
group of nodes presenting a higher density of lines, i.e.
which are functionally connected.
factors or miRNAs and their targets [81,82]; genetic networks
connect genes together if there is evidence for gene–gene
interaction or epistasis [83]; and phenotype networks, where
genes with similar gene- or protein-expression proﬁles can
be linked together and the resulting co-expression clusters,
or modules, can be correlated with a phenotype [84,85]. The
goal of many  studies using networks is to discover modules
of closely inter-connected genes that function together as
a unit. Some functional gene modules are conserved across
large evolutionary distances and are thought to represent
the fundamental building blocks of molecular processes [86].
Discovery of such modules in human disease will there-
fore provide the building blocks for understanding disease
progression and potential therapeutic intervention points.
Cross-species conservation of gene modules can also identify
relevant model organisms and assays for drug screening.
Networks have been successfully used to identify key genes
involved in the pathogenesis of many  diseases. A recent study
on autism focused on trying to understand major pathways
and molecular functions affected by the disease, by looking
at rare variants in a network-based approach. By looking at
the rare variants in the context of a network of known inter-
actions, the authors were able to show that the functional
clusters most often hit were related to a number of molecular
processes, including actin network dynamics and reorganiza-
tion, synaptogenesis and axonogenesis [87]. Networks have
also been used for the study of somatic mutations occurring in
metastatic melanoma. In a recent study, a large protein inter-
action network was used to ﬁnd sub-clusters or modules of
interacting proteins that were affected in tumors. Whilst the
genes affected by somatic copy number variants were different
in different tumors, they often occurred in the same modules
of proteins, which were in turn associated with cell cycle and
apoptotic functions [88]. These two examples used biological
networks composed of known protein interaction and path-
way data, and mapped genetic observations to these networks.
An alternative approach is to generate a network from the data i c s 1 ( 2 0 1 3 ) 25–37
itself, rather than from additional functional information. The
advantage of this approach is that the network reﬂects the
data of a speciﬁc controlled experiment rather than data from
many different experiments, often from many  different cell
types. Because the network does not rely on known relation-
ships, observations made in such networks can lead to truly
novel discoveries. A recent example of such a study used
global gene expression proﬁles from human pancreatic islets
and identiﬁed a network module containing Sfrp4, which was
strongly over-expressed in non-insulin-dependent diabetes
mellitus patients and affected insulin secretion [85,89,90]. Net-
work theory has shown that the most connected genes within
biological networks (the hub genes) are often the most essen-
tial [76]. In the abovementioned study, Sfrp4 was identiﬁed
as a hub gene in the module, and was as such identiﬁed as
an important putative target affecting insulin secretion. The
identiﬁcation of this gene would not have been possible with-
out looking at the interconnectedness of the genes in the
context of all the experimental data.
Considering networks of pathways (instead of single
gene products) as being affected comparing 2 phenotypes
is particularly adapted to the dissection of ﬁne metabolic
modulations, particularly in experimental settings associated
with high biological variation [91], as with human samples.
Moreover, network biology better reﬂects the physiological
situation–where the modulation of a given molecule of inter-
est affects many  different factors–topologically visible as
clusters (Fig. 6). This integration allows the exploitation of the
complementary aspects of different data sets, going one step
further than simply considering common gene product reg-
ulation among mRNA  and proteins. Known protein–protein
interactions and pathway database information can also be
used to weight experimental relationships and complement
the network. Then, interpretation of the network can be per-
formed using gene-set or gene-ontology enrichment analysis
[92], or other bioinformatics tools [93]. Finally, validation of
such results can be performed in vivo or using biological
models, reproducing the same phenotype by modulating the
pathway of interest [74]. To the best of our knowledge, this type
of approach has never been applied to identify the modulators
of platelet reactivity. Of note, since current antiplatelet drugs
mainly target the TxA2 and ADP pathways, the identiﬁcation
of other pathways modulating on-treatment platelet reactivity
in cardiovascular patients could have a major impact on both
our understanding of platelet physiology and on the manage-
ment of platelet hyperreactivity in these high-risk patients.
4.  Conclusion
The identiﬁcation of the modulators of platelet reactivity is
of utmost importance since it may deﬁne new targets for the
prevention of recurrence of ischemic events, and help to tai-
lor antithrombotic therapy according to the characteristics of
each patient. Moreover, the identiﬁcation of modulators of
platelet reactivity may also be of importance in the inves-
tigation of patients with mild bleeding disorders [94]. The
combination of several omic data sets is a promising approach
to having a more  global view of the candidate pathways mod-
ulating platelet reactivity. Network biology offers the powerful
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ool necessary for the integration of those data sets of different
rigins. This is of particular interest when considering pheno-
ypes relying on the study of very ﬁne metabolic modulations
n samples presenting biological variability, as human sam-
les do. Furthermore, it allows us to work out the interactions
etween different pathways and is thus more  representative
f the physiological situation.
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